{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:16:35Z","timestamp":1789161395752,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OR13-21"],"award-info":[{"award-number":["W.OR13-21"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OR15-10"],"award-info":[{"award-number":["W.OR15-10"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OR16-07"],"award-info":[{"award-number":["W.OR16-07"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tex Net"},{"name":"Sophia Foundation for Medical Research (SSWO)","award":["S17-32"],"award-info":[{"award-number":["S17-32"]}]},{"name":"Metakids","award":["2016-063"],"award-info":[{"award-number":["2016-063"]}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Colciencias and Sanofi Genzyme"},{"name":"TKI-programme Life Sciences & Health","award":["LSHM16008"],"award-info":[{"award-number":["LSHM16008"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jpeds.2017.11.046","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T17:23:11Z","timestamp":1518024191000},"page":"236-243.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy"],"prefix":"10.1016","volume":"195","author":[{"given":"Esther","family":"Poelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Hoogeveen-Westerveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian A.","family":"Kroos-de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees J.","family":"Bronsema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico C.","family":"van de Merbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7042-2482","authenticated-orcid":false,"given":"W.W.M. Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2017.11.046_bib0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0020","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0035","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid alpha-glucosidase \u2014 major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0050","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","article-title":"Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience","volume":"33","author":"Chakrapani","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0065","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study","volume":"39","author":"van Gelder","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/8904_2014_392","article-title":"Outcome of patients with classical infantile Pompe disease receiving enzyme replacement therapy in Germany","volume":"20","author":"Hahn","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10545-015-9898-5","article-title":"Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy","volume":"39","author":"Broomfield","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0085","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"de Vries","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0095","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00246-006-0101-5","article-title":"Left ventricular mass in 169 healthy children and young adults assessed by three-dimensional echocardiography","volume":"28","author":"Poutanen","year":"2007","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0115","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0735-1097(88)80061-5","article-title":"Left ventricular mass in children and adolescents","volume":"12","author":"Devereux","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0120","series-title":"Motor assessment of the developing infant","author":"Piper","year":"1994"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0125","series-title":"Bayley scales of infant development","author":"Bayley","year":"1993"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0130","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1021\/acs.analchem.5b00169","article-title":"Absolute quantification of the total and antidrug antibody-bound concentrations of recombinant human alpha-glucosidase in human plasma using protein G extraction and LC-MS\/MS","volume":"87","author":"Bronsema","year":"2015","journal-title":"Anal Chem"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0135","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/hmg\/3.12.2213","article-title":"The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II","volume":"3","author":"Hermans","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/humu.22705","article-title":"Identification and characterization of aberrant GAA pre-mRNA splicing in Pompe disease using a generic approach","volume":"36","author":"Bergsma","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0145","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1006\/bbrc.1994.2360","article-title":"Deletion of exon 18 is a frequent mutation in glycogen storage disease type II","volume":"203","author":"Van der Kraan","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0150","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0155","doi-asserted-by":"crossref","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ymgmr.2015.05.004","article-title":"Immune tolerance strategies in siblings with infantile Pompe disease-advantages for a preemptive approach to high-sustained antibody titers","volume":"4","author":"Stenger","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.jpeds.2017.11.046_bib0165","series-title":"Enzyme Therapy in Non-classic Pompe's Disease: Safety and efficacy of recombinant human a-glucosidase from milk of transgenic rabbits and from Chinese hamster ovary cells. Doctoral's thesis","author":"Winkel","year":"2004"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347617316025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347617316025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T21:08:44Z","timestamp":1617570524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347617316025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":32,"alternative-id":["S0022347617316025"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2017.11.046","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2017.11.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}